Biotech: Page 93

  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    What could help biotech close out 2019 stronger? Analysts pick 3 events to watch

    Biotech generally underperformed the market so far this year. Updates from Amgen, Roche and Novartis could deliver a needed boost, analysts at Credit Suisse say.

    By Andrew Dunn • Sept. 4, 2019
  • Image attribution tooltip
    Ryan McKnight, Vertex Pharmaceuticals Inc.
    Image attribution tooltip

    Vertex to buy preclinical biotech for $950M, searching a Type 1 diabetes cure

    Acquiring Semma Therapeutics fulfills CEO Jeffrey Leiden's promise that Vertex would explore "potentially larger" deals than it's done in the past.

    By Andrew Dunn • Sept. 3, 2019
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendlineâž”
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

    By BioPharma Dive staff
  • Image attribution tooltip
    NPR
    Image attribution tooltip

    UniQure stays a step ahead in hemophilia B

    Seeing high interest from patients and study investigators, uniQure is enrolling six more participants than planned in its Phase 3 gene therapy study.

    By • Sept. 3, 2019
  • Image attribution tooltip
    Elizabeth Regan/BioPharma Dive
    Image attribution tooltip

    Medicines Co.'s cholesterol drug looks good to take on PCSK9 rivals

    Data show inclisiran more or less matched Repatha and Praluent on cholesterol lowering, but the drug will need a smart launch, and possibly a partner, to compete.

    By • Updated Sept. 3, 2019
  • Image attribution tooltip
    Cassi Josh, edited by BioPharma Dive
    Image attribution tooltip

    Alexion shares slide on Amgen patent challenge to top-seller

    A surprise decision by the U.S. patent office to review three patents held by Alexion on its drug Soliris renewed fears of earlier-than-expected competition.

    By • Aug. 30, 2019
  • Image attribution tooltip
    Amgen
    Image attribution tooltip
    Deep Dive

    Amgen puts its KRAS hopes on 'Navy Seals' team of drug hunters

    Found in many solid tumors, mutant KRAS is cancer research's white whale. Amgen's drug looks the most promising to emerge from decades of failed efforts, but others are close behind. 

    By • Aug. 30, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Deep Dive

    Amyloid's last hope? Prevention studies next big test for Alzheimer's research

    The DIAN-TU trial, studying patients genetically predisposed to Alzheimer's, could help decide the fate of what's been the dominant hypothesis of the disease's cause.

    By • Aug. 29, 2019
  • A Regeneron sign in front of a building.
    Image attribution tooltip
    Courtesy of Regeneron Pharmaceuticals
    Image attribution tooltip

    Amgen patents on Repatha invalid, judge rules in reversal

    The decision by Judge Richard Andrews overturns a February jury verdict that affirmed two patents held by Amgen on the cholesterol drug.

    By • Aug. 28, 2019
  • Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Immatics shows Celgene isn't done stocking cell therapy pipeline

    As its takeover by Bristol-Myers nears closing, Celgene is committing $75 million to research into T-cell redirecting technology.

    By • Aug. 28, 2019